Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics. Issue 9 (10th March 2021)
- Record Type:
- Journal Article
- Title:
- Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics. Issue 9 (10th March 2021)
- Main Title:
- Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
- Authors:
- Mou, Haibo
Yang, Qiu‐an
Yu, Lanfang
Wang, Ting
Liu, Kui
Shen, Rong
Pan, Xuedong
Dai, Yi
Wan, Qing
Zhou, Fangling
Qian, Lili
Chen, Donglin
Yau, Thomas
Dong, Xiaowei
Wang, Xuemei
Wang, Shuang - Abstract:
- Abstract: Background and Aim: Programmed cell death‐ligand 1 (PD‐L1) immunohistochemistry score has been approved as the predictive biomarker for anti‐PD1/PD‐L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti‐PD1/PD‐L1 therapy showed promising results. However, less is known about the PD‐L1 immunohistochemistry score and factors correlated with it in hepatocellular carcinoma. We investigated PD‐L1 immunohistochemistry scores in a large cohort of hepatocellular carcinoma, as well as its correlation with various clinical and genomic factors. Methods: Immunohistochemistry was performed to detect the expression of PD‐L1 protein in 315 hepatocellular carcinoma tissues. All slides were independently reviewed by three senior pathologists. Next‐generation YS panel (450 genes) sequencing was performed on 309 patients. Results: Higher PD‐L1 expression as measured by combined positive score (CPS) was associated with increased Edmondson–Steiner grade (grade III vs II, P = 0.041) and TP53 mutations ( P = 0.021). PD‐L1 CPS had no correlation with tumor mutational burden (Spearman's correlation coefficient 0.067). PD‐L1 CPS was not significantly associated with hepatitis B virus infection. Conclusions: Our data indicated that patients with higher Edmondson–Steiner grade (grade III) had significantly higher PD‐L1 CPS than patients with lower Edmondson–Steiner grade (grade II). Patients withAbstract: Background and Aim: Programmed cell death‐ligand 1 (PD‐L1) immunohistochemistry score has been approved as the predictive biomarker for anti‐PD1/PD‐L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti‐PD1/PD‐L1 therapy showed promising results. However, less is known about the PD‐L1 immunohistochemistry score and factors correlated with it in hepatocellular carcinoma. We investigated PD‐L1 immunohistochemistry scores in a large cohort of hepatocellular carcinoma, as well as its correlation with various clinical and genomic factors. Methods: Immunohistochemistry was performed to detect the expression of PD‐L1 protein in 315 hepatocellular carcinoma tissues. All slides were independently reviewed by three senior pathologists. Next‐generation YS panel (450 genes) sequencing was performed on 309 patients. Results: Higher PD‐L1 expression as measured by combined positive score (CPS) was associated with increased Edmondson–Steiner grade (grade III vs II, P = 0.041) and TP53 mutations ( P = 0.021). PD‐L1 CPS had no correlation with tumor mutational burden (Spearman's correlation coefficient 0.067). PD‐L1 CPS was not significantly associated with hepatitis B virus infection. Conclusions: Our data indicated that patients with higher Edmondson–Steiner grade (grade III) had significantly higher PD‐L1 CPS than patients with lower Edmondson–Steiner grade (grade II). Patients with TP53 mutations had significantly higher PD‐L1 expression. … (more)
- Is Part Of:
- Journal of gastroenterology and hepatology. Volume 36:Issue 9(2021)
- Journal:
- Journal of gastroenterology and hepatology
- Issue:
- Volume 36:Issue 9(2021)
- Issue Display:
- Volume 36, Issue 9 (2021)
- Year:
- 2021
- Volume:
- 36
- Issue:
- 9
- Issue Sort Value:
- 2021-0036-0009-0000
- Page Start:
- 2601
- Page End:
- 2609
- Publication Date:
- 2021-03-10
- Subjects:
- E–S grade -- Hepatocellular carcinoma -- Immunohistochemistry -- PD‐L1 -- TP53 -- Tumor mutational burden
Gastroenterology -- Periodicals
Digestive organs -- Diseases -- Periodicals
Liver -- Diseases -- Periodicals
Gastroenterology -- Periodicals
Liver Diseases -- Periodicals
616.33 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1440-1746 ↗
http://onlinelibrary.wiley.com/ ↗
http://www.blackwell-synergy.com/loi/jgh ↗ - DOI:
- 10.1111/jgh.15475 ↗
- Languages:
- English
- ISSNs:
- 0815-9319
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4987.615000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19007.xml